CREATE Medicines secured a $122 million Series B round to advance its in vivo CAR platform, with lead assets spanning autoimmune disease and oncology. The company’s proprietary mRNA-LNP platform is designed to engineer immune cells inside the body for repeat dosing and off-the-shelf scalability. In autoimmune disease, CRT-402 targets CD19 for immune depletion and durable B-cell depletion shown in non-human primates. A second program targets CD19 and BCMA. In oncology, the company reported early responses for MT-303 in frontline hepatocellular carcinoma and said it has already dosed more than 50 patients across clinical in vivo CAR programs. Funds are intended to support pipeline progression and internal manufacturing capacity.